PubMed

HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005.

Köninki K, Tanner M, Auvinen A, Isola J.

Breast Cancer Res. 2009;11(3):R37. Epub 2009 Jun 18.PMID: 19538720 [PubMed - indexed for MEDLINE]Related articlesFree article

Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women.

Gammon MD, Hibshoosh H, Terry MB, Bose S, Schoenberg JB, Brinton LA, Bernstein JL, Thompson WD.

Cancer Epidemiol Biomarkers Prev. 1999 May;8(5):413-9.PMID: 10350436 [PubMed - indexed for MEDLINE]Related articlesFree article

Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.

Glass AG, Lacey JV Jr, Carreon JD, Hoover RN.

J Natl Cancer Inst. 2007 Aug 1;99(15):1152-61. Epub 2007 Jul 24.PMID: 17652280 [PubMed - indexed for MEDLINE]Related articlesFree article

Her-2/neu amplification and breast cancer survival: results from the Shanghai breast cancer study.

Beeghly-Fadiel A, Kataoka N, Shu XO, Cai Q, Deming SL, Gao YT, Zheng W.

Oncol Rep. 2008 May;19(5):1347-54.PMID: 18425397 [PubMed - indexed for MEDLINE]Related articles

Trends in breast cancer by race and ethnicity: update 2006.

Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M.

CA Cancer J Clin. 2006 May-Jun;56(3):168-83.PMID: 16737949 [PubMed - indexed for MEDLINE]Related articlesFree article

Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998.

Li CI, Daling JR, Malone KE.

J Clin Oncol. 2003 Jan 1;21(1):28-34.PMID: 12506166 [PubMed - indexed for MEDLINE]Related articles

Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.

Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J.

Clin Cancer Res. 2003 Mar;9(3):923-30.PMID: 12631589 [PubMed - indexed for MEDLINE]Related articlesFree article

Her-2/neu oncogene amplification and protein over-expression in interval and screen-detected breast cancers.

Anttinen J, Kuopio T, Nykanen M, Torkkeli H, Saari U, Juhola M.

Anticancer Res. 2003 Sep-Oct;23(5b):4213-8.PMID: 14666627 [PubMed - indexed for MEDLINE]Related articles

Estimating risk of breast cancer from population incidence affected by widespread mammographic screening.

Taylor R, Boyages J.

J Med Screen. 2001;8(2):73-6.PMID: 11480447 [PubMed - indexed for MEDLINE]Related articles

Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women.

Jemal A, Ward E, Thun MJ.

Breast Cancer Res. 2007;9(3):R28.PMID: 17477859 [PubMed - indexed for MEDLINE]Related articlesFree article

Trends in incidence rates of invasive lobular and ductal breast carcinoma.

Li CI, Anderson BO, Daling JR, Moe RE.

JAMA. 2003 Mar 19;289(11):1421-4.PMID: 12636465 [PubMed - indexed for MEDLINE]Related articlesFree article

Molecular subtypes of breast cancers detected in mammography screening and outside of screening.

Sihto H, Lundin J, Lehtimäki T, Sarlomo-Rikala M, Bützow R, Holli K, Sailas L, Kataja V, Lundin M, Turpeenniemi-Hujanen T, Isola J, Heikkilä P, Joensuu H.

Clin Cancer Res. 2008 Jul 1;14(13):4103-10.PMID: 18593987 [PubMed - indexed for MEDLINE]Related articlesFree article

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ.

J Natl Cancer Inst. 2003 Jan 15;95(2):142-53.PMID: 12529347 [PubMed - indexed for MEDLINE]Related articlesFree article

Mammography screening for breast cancer in Copenhagen April 1991-March 1997. Mammography Screening Evaluation Group.

Lynge E.

APMIS Suppl. 1998;83:1-44.PMID: 9850674 [PubMed - indexed for MEDLINE]Related articles

Changes in incidence of in situ and invasive breast cancer by histology type following mammography screening.

Luke C, Priest K, Roder D.

Asian Pac J Cancer Prev. 2006 Jan-Mar;7(1):69-74.PMID: 16629519 [PubMed - indexed for MEDLINE]Related articles

Incidence of invasive breast cancer and ductal carcinoma in situ in a screening program by age: should older women continue screening?

Erbas B, Amos A, Fletcher A, Kavanagh AM, Gertig DM.

Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1569-73.PMID: 15466971 [PubMed - indexed for MEDLINE]Related articlesFree article

The incidence of breast cancer from screening women according to predicted family history risk: Does annual clinical examination add to mammography?

Gui GP, Hogben RK, Walsh G, A'Hern R, Eeles R.

Eur J Cancer. 2001 Sep;37(13):1668-73.PMID: 11527694 [PubMed - indexed for MEDLINE]Related articles

Pathology of borderline HER-2/neu breast carcinoma: a biologically distinct phenotype.

Killeen JL, Ortega-Lopez A, Shaha J, Shaha SH, Fu JB.

Breast Cancer Res Treat. 2006 Jul;98(1):99-108. Epub 2006 Mar 15.PMID: 16538540 [PubMed - indexed for MEDLINE]Related articles

The greater impact of menopause on ER- than ER+ breast cancer incidence: a possible explanation (United States).

Tarone RE, Chu KC.

Cancer Causes Control. 2002 Feb;13(1):7-14.PMID: 11899120 [PubMed - indexed for MEDLINE]Related articles

Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.

Nyagol J, Nyong'o A, Byakika B, Muchiri L, Cocco M, de Santi MM, Spina D, Bellan C, Lazzi S, Kostopoulos I, Luzi P, Leoncini L.

Anal Quant Cytol Histol. 2006 Apr;28(2):97-103.PMID: 16637512 [PubMed - indexed for MEDLINE]Related articles